Salarius Pharmaceuticals Stock Revenue
| SLRX Stock | USD 1.37 0.09 6.16% |
Salarius Pharmaceuticals fundamentals help investors to digest information that contributes to Salarius Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Salarius Stock. The fundamental analysis module provides a way to measure Salarius Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Salarius Pharmaceuticals stock.
| Last Reported | Projected for Next Year |
Salarius | Revenue |
Salarius Pharmaceuticals Company Revenue Analysis
Salarius Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Salarius
Projected quarterly revenue analysis of Salarius Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Salarius Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Salarius Pharmaceuticals' stock price.
Salarius Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Salarius Pharmaceuticals is extremely important. It helps to project a fair market value of Salarius Stock properly, considering its historical fundamentals such as Revenue. Since Salarius Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Salarius Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Salarius Pharmaceuticals' interrelated accounts and indicators.
| 0.27 | -0.82 | -0.85 | -0.7 | 0.83 | ||
| 0.27 | -0.27 | -0.22 | -0.04 | 0.34 | ||
| -0.82 | -0.27 | 0.9 | 0.91 | -0.99 | ||
| -0.85 | -0.22 | 0.9 | 0.76 | -0.92 | ||
| -0.7 | -0.04 | 0.91 | 0.76 | -0.87 | ||
| 0.83 | 0.34 | -0.99 | -0.92 | -0.87 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Salarius Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Salarius Pharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Salarius Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Salarius Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Salarius Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Salarius Pharmaceuticals by comparing valuation metrics of similar companies.Salarius Pharmaceuticals is currently under evaluation in revenue category among its peers.
Salarius Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Salarius Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Salarius Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Salarius Pharmaceuticals' value.| Shares | Vanguard Group Inc | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 22.8 K | Tower Research Capital Llc | 2024-06-30 | 3.2 K | Ubs Group Ag | 2024-06-30 | 113 | Advisor Group Holdings, Inc. | 2024-06-30 | 53.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 14.0 | Bank Of America Corp | 2024-06-30 | 6.0 | Wells Fargo & Co | 2024-06-30 | 1.0 | Blackrock Inc | 2024-06-30 | 1.0 | Horizon Asset Management Inc/ny | 2024-06-30 | 0.0 |
Salarius Fundamentals
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | (851.09 K) | ||||
| Shares Outstanding | 1.44 M | ||||
| Shares Owned By Insiders | 2.52 % | ||||
| Shares Owned By Institutions | 0.36 % | ||||
| Number Of Shares Shorted | 65.04 K | ||||
| Price To Book | 0.72 X | ||||
| Price To Sales | 18.12 X | ||||
| Gross Profit | (15.84 M) | ||||
| EBITDA | (12.88 K) | ||||
| Net Income | (12.54 M) | ||||
| Cash And Equivalents | 22.65 M | ||||
| Cash Per Share | 10.09 X | ||||
| Total Debt | 289.64 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 8.31 X | ||||
| Book Value Per Share | 10.74 X | ||||
| Cash Flow From Operations | (12.85 M) | ||||
| Short Ratio | 0.08 X | ||||
| Earnings Per Share | (5.14) X | ||||
| Target Price | 26.0 | ||||
| Beta | 0.93 | ||||
| Market Capitalization | 2.1 M | ||||
| Total Asset | 6.59 M | ||||
| Retained Earnings | (76.35 M) | ||||
| Working Capital | 5.22 M | ||||
| Current Liabilities | 1.97 M | ||||
| Net Asset | 6.59 M |
About Salarius Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Salarius Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Salarius Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Salarius Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.